Drug-induced movement disorders

被引:28
|
作者
Zadori, Denes [1 ]
Veres, Gabor [1 ]
Szalardy, Levente [1 ]
Klivenyi, Peter [1 ]
Vecsei, Laszlo [1 ,2 ]
机构
[1] Univ Szeged, Albert Szent Gyorgyi Clin Ctr, Dept Neurol, Fac Med, H-6725 Szeged, Hungary
[2] MTA SZTE Neurosci Res Grp, H-6725 Szeged, Hungary
关键词
basal ganglia; drug-induced side-effects; movement disorders; tardive syndromes; RESTLESS LEGS SYNDROME; ACUTE DYSTONIC REACTION; DEEP BRAIN-STIMULATION; TARDIVE-DYSKINESIA; PARKINSONS-DISEASE; ATYPICAL ANTIPSYCHOTICS; INDUCED MYOCLONUS; INDUCED CHOREA; DOUBLE-BLIND; EXTRAPYRAMIDAL SYMPTOMS;
D O I
10.1517/14740338.2015.1032244
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Drug-induced movement disorders (DIMDs) can be elicited by several kinds of pharmaceutical agents. The major groups of offending drugs include antidepressants, antipsychotics, antiepileptics, antimicrobials, antiarrhythmics, mood stabilisers and gastrointestinal drugs among others. Areas covered: This paper reviews literature covering each movement disorder induced by commercially available pharmaceuticals. Considering the magnitude of the topic, only the most prominent examples of offending agents were reported in each paragraph paying a special attention to the brief description of the pathomechanism and therapeutic options if available. Expert opinion: As the treatment of some DIMDs is quite challenging, a preventive approach is preferable. Accordingly, the use of the offending agents should be strictly limited to appropriate indications and they should be applied in as low doses and as short duration as the patient's condition allows. As most of DIMDs are related to an unspecific adverse action of medications in the basal ganglia and the cerebellum, future research should focus on better characterisation of the neurochemical profile of the affected functional systems, in addition to the development of drugs with higher selectivity and better side-effect profile.
引用
收藏
页码:877 / 890
页数:14
相关论文
共 50 条
  • [1] Drug-induced movement disorders
    Diederich, NJ
    Goetz, CG
    NEUROLOGIC CLINICS, 1998, 16 (01) : 125 - +
  • [2] Drug-induced movement disorders
    Duma, Stephen R.
    Fung, Victor S. C.
    AUSTRALIAN PRESCRIBER, 2019, 42 (02) : 56 - 61
  • [3] Drug-induced movement disorders
    Rodnitzky, RL
    CLINICAL NEUROPHARMACOLOGY, 2002, 25 (03) : 142 - 152
  • [4] Drug-Induced Movement Disorders
    Pandey, Sanjay
    Pitakpatapee, Yuvadee
    Saengphatrachai, Weerawat
    Chouksey, Anjali
    Tripathi, Madhavi
    Srivanitchapoom, Prachaya
    SEMINARS IN NEUROLOGY, 2023, 43 (01) : 35 - 47
  • [5] DRUG-INDUCED MOVEMENT DISORDERS
    NORTH, RR
    POSTGRADUATE MEDICINE, 1971, 50 (03) : 180 - &
  • [6] Drug-Induced Movement Disorders
    Félix Javier Jiménez-Jiménez
    Pedro José García-Ruiz
    José Antonio Molina
    Drug Safety, 1997, 16 : 180 - 204
  • [7] Drug-induced movement disorders
    JimenezJimenez, FJ
    GarciaRuiz, PJ
    Molina, JA
    DRUG SAFETY, 1997, 16 (03) : 180 - 204
  • [8] Drug-induced Movement Disorders
    Mehta, Shyamal H.
    Morgan, John C.
    Sethi, Kapil D.
    NEUROLOGIC CLINICS, 2015, 33 (01) : 153 - +
  • [9] DRUG-INDUCED MOVEMENT-DISORDERS
    GERSHANIK, OS
    CURRENT OPINION IN NEUROLOGY AND NEUROSURGERY, 1993, 6 (03): : 369 - 376
  • [10] DRUG-INDUCED MOVEMENT-DISORDERS
    OWEN, RT
    PHARMACY INTERNATIONAL, 1980, 1 (09): : 181 - 183